"The interim results demonstrated a highly differentiated clinical profile for TUB-040 in the ADC field, with anti-tumor activity beginning at low doses with a broad therapeutic window that could ...
MUNICH, October 19, 2025--(BUSINESS WIRE)--Tubulis today announced positive early clinical data from its NAPISTAR1-01 Phase I/IIa study (NCT06303505) in a late-breaking oral presentation at the ...
TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients At data-cut-off on September 1, 2025 ...
However, now it is far more valuable in that it was able to meet the primary endpoint of progression-free survival [PFS] in its phase 3 ROSELLA study, which treated patients with PROC. This tees up ...
(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer or ...
(RTTNews) - AbbVie (ABBV) announced that final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE or mirvetuximab ...
Python processing files were written in Jupyter notebooks and converted to python scripts using jupytext. They can be converted back to Jupyter notebooks. All data were recorded as single ping for all ...
Create a data proc HA cluster using the command below gcloud dataproc clusters create ${CLUSTER_NAME} \ --region us-central1 --zone us-central1-a \ --image-version 2.0-ubuntu18 \ --num-masters 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback